Research analysts covering RF Acquisition Corp II.
Recent press releases and 8-K filings for RFAI.
RF Acquisition Corp II Shareholders Approve Business Combination Deadline Extension
RFAI
Proxy Vote Outcomes
M&A
- On November 10, 2025, RF Acquisition Corp II (RFAI) shareholders approved amendments to extend the deadline for consummating a business combination.
- The new termination date for completing a business combination is August 15, 2026, allowing for up to nine one-month extensions from the original November 15, 2025 deadline.
- Each monthly extension requires a deposit of $0.03 for each public share not redeemed, with a maximum of $60,000, into the Trust Account.
- Both the Articles Amendment Proposal and the Trust Agreement Amendment Proposal were approved with 9,600,561 votes FOR.
Nov 14, 2025, 9:30 PM
RF Acquisition Corp II Enters Business Combination Agreement with Nanyang Biologics
RFAI
M&A
New Projects/Investments
- RF Acquisition Corp II (RFAI) has entered into a business combination agreement with Nanyang Biologics Pte. Ltd. (NYB), with the goal of listing NYB on Nasdaq under the reserved ticker symbol "NYB".
- The proposed transaction values NYB at approximately $1.5 billion in pre-transaction equity value.
- NYB is an AI-driven drug discovery and biotechnology company utilizing its proprietary Vecura™ AI platform and DTIGN engine, with a pipeline of drug candidates targeting oncology, cardiovascular, and mental health, including the first-in-class oncology therapy NB-A002.
- The closing of the transaction is expected in the first or second quarter of 2026, subject to shareholder approval and customary closing conditions.
Oct 2, 2025, 11:50 AM
RF Acquisition Corp II Announces Business Combination with Nanyang Biologics Pte. Ltd.
RFAI
M&A
New Projects/Investments
- RF Acquisition Corp II (RFAI) entered into a business combination agreement with Nanyang Biologics Pte. Ltd. (NYB) on October 2, 2025, in a transaction that gives NYB approximately $1.5 billion in pre-transaction equity value.
- The proposed transaction aims to make NYB a publicly listed company on Nasdaq under the reserved ticker symbol "NYB".
- NYB's existing shareholders will retain a majority of the combined company's outstanding shares and designate a majority of the director nominees for the board.
- The closing of the transaction is expected in the first or second quarter of 2026, subject to shareholder approval and customary closing conditions.
Oct 2, 2025, 11:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more